Sharps Technology Reports Strong Solana Staking Income
Rhea-AI Summary
Sharps Technology (NASDAQ:STSS) reported treasury and operational updates on January 26, 2026 focused on its Solana-based digital asset strategy. The company said its validator partners have generated approximately 7% gross APY since inception, outperforming the Solana network average, and that nearly all of its SOL holdings are currently staked. STSS stated it has no corporate debt and maintains sufficient operating capital. In January the company announced a lock-up agreement with its strategic advisor restricting sales of advisory warrants and confirmed no prior sales or hedging, and launched a jointly supported institutional-grade Solana validator in partnership with Coinbase to which it delegated a portion of its SOL treasury holdings.
Positive
- ~7% gross APY from validator staking since inception
- Nearly all SOL holdings staked, generating ongoing yield
- No corporate debt and sufficient operating capital
- Launched institutional-grade Solana validator in partnership with Coinbase
- Lock-up agreement restricts advisor sales of warrants and shares
Negative
- Reported yield is gross APY before fees, so net yield may be lower
Key Figures
Market Reality Check
Peers on Argus
STSS fell 1.36% with peers OSUR, STXS, INFU, NYXH and UTMD also negative (down between 0.62% and 3.5%), indicating broader softness in medical instruments despite crypto-focused news.
Previous Crypto Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Solana validator launch | Positive | +7.4% | Launched institutional-grade Solana validator with Coinbase, delegating >2M SOL. |
| Oct 09 | Treasury strategy expansion | Positive | +0.5% | Expanded Solana treasury strategy via Coinbase Prime custody and OTC desk. |
| Sep 29 | Crypto.com partnership | Positive | +2.7% | Partnered with Crypto.com to manage >2M SOL and deploy capital in ecosystem. |
Crypto-treasury news has consistently aligned with positive one-day moves, averaging 3.51% across prior Solana-focused updates.
Over recent months, STSS has repeatedly highlighted its Solana-based digital asset strategy, including partnerships with Coinbase and Crypto.com and deployment of over 2 million SOL via institutional custody and validator infrastructure. Prior crypto-tag releases on Sep 29, 2025, Oct 9, 2025, and Jan 12, 2026 all saw positive next-day reactions. Today’s staking-income update continues that theme of deepening integration with Solana and institutional validator partners.
Historical Comparison
In the past year STSS issued 3 Solana-focused crypto-treasury updates, averaging a 3.51% next-day move. This staking-income update fits the same pattern of infrastructure and treasury optimization news.
Crypto-tag history shows progression from initial Solana treasury partnerships with Crypto.com and Coinbase to launching an institutional-grade validator, with this update emphasizing ongoing staking yields and validator integration.
Regulatory & Risk Context
An effective S-3 resale registration filed on Oct 23, 2025 allows selling stockholders to resell registered shares and warrant shares. The company would not receive proceeds from resales but could receive up to $614,837,807.75 in gross proceeds if all registered warrants are exercised, alongside extensive risk disclosures tied to its SOL-focused digital asset strategy.
Market Pulse Summary
This announcement underscores STSS’s evolution into a Solana-centric digital asset treasurer, emphasizing ~7% gross APY from staking and nearly fully staked SOL holdings. It also highlights institutional-grade validator partnerships and a lock-up on advisory warrants. In context of prior large PIPE funding and an S-3 resale registration with significant warrant capacity, investors may monitor staking stability, Solana price swings, and execution of the broader medical device and digital asset strategy.
Key Terms
staking technical
annual percentage yield (apy) financial
validator technical
warrants financial
AI-generated analysis. Not financial advice.
NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (“STSS” or the “Company”), a medical device company implementing a Solana-based digital asset treasury strategy, today issued an update on its treasury and recent operational highlights.
Treasury Updates
- Staking: Since inception, STSS’s validator partners have generated ~
7% gross annual percentage yield (APY) before fees, outperforming the Solana network average. Nearly all of the Company’s SOL holdings are currently staked. - Balance Sheet: STSS continues to maintain sufficient operating capital and has no corporate debt.
Recent Operational Highlights
- In January, STSS announced a lock-up agreement with its Strategic Advisor to restrict sales of its advisory warrants and any underlying shares. The Strategic Advisor has also confirmed none of its advisory warrants and underlying shares have been sold or hedged prior to this agreement.
- In January, STSS launched a jointly supported institutional-grade Solana validator in partnership with Coinbase, to which STSS has delegated a portion of its SOL treasury holdings.
“STSS continues to deliver strong revenue from its SOL holdings due to its integration with institutional-quality staking infrastructure,” said James Zhang, Strategic Advisor to STSS. “Our partnerships with leading validator platforms, combined with institutional-grade controls and execution discipline, position STSS to capitalize on the financial benefits of the Solana network.”
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this release other than statements of historical fact are forward-looking statements, including statements regarding the Company’s execution of its Solana digital asset treasury strategy and the potential opportunities such initiatives may create for retail and institutional audiences. Forward-looking statements are based on current expectations, assumptions, and beliefs, and involve risks and uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others: the Company’s ability to successfully execute its Solana treasury strategy; volatility in the market price of SOL and other digital assets; changes in the regulatory or legal environment; competitive pressures; and general market, economic, and business conditions. Additional risks are described in the “Risk Factors” section of the Company’s filings with the Securities and Exchange Commission (the “SEC”), which are available on the SEC’s website at www.sec.gov.
Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise these statements, whether as a result of new information, future developments, or otherwise, except as required by law.
About Sharps Technology
Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class, smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities that incorporate syringe technologies that use both passive and active safety features.
The Company has adopted a digital asset treasury strategy focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises to power on-chain yield generation with the Solana Ecosystem.
Contact
FAQ
What staking yield did Sharps Technology (STSS) report on January 26, 2026?
Does STSS hold debt after the January 26, 2026 update?
How much of STSS's SOL treasury is staked according to the January 26, 2026 update?
What is the significance of the Coinbase partnership announced by STSS in January 2026?
What did the lock-up agreement announced January 2026 do for STSS shareholders?
Is the reported 7% APY net of fees for STSS staking income?
